Descriptive Pharmacoepidemiological Study of Patients Treated With Iressa (EPIDAURE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01448187 |
|
Recruitment Status
:
Completed
First Posted
: October 7, 2011
Last Update Posted
: July 4, 2016
|
Sponsor:
AstraZeneca
Information provided by (Responsible Party):
AstraZeneca
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The aim of the study is to describe the characteristics of patients treated with Iressa (particularly age, gender, phenotype, histology and stage of disease, line of treatment and previous treatments, smoking history, conditions of initiation of treatment (presence of an EGFR-activating mutation) and to evaluate the impact of treatment on the health of the population concerned in terms of morbidity and mortality (clinical benefit, safety,...) and quality of life
| Condition or disease |
|---|
| Lung Cancer |
Descriptive pharmacoepidemiological study of patients treated with Iressa
| Study Type : | Observational |
| Actual Enrollment : | 361 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | Descriptive Pharmacoepidemiological Study of Patients Treated With Iressa |
| Study Start Date : | January 2012 |
| Actual Primary Completion Date : | March 2015 |
| Actual Study Completion Date : | March 2015 |
Resource links provided by the National Library of Medicine
Genetics Home Reference related topics:
Lung cancer
U.S. FDA Resources
Primary Outcome Measures
:
- The Overall survival [ Time Frame: 24 months ]
- The progression free survival [ Time Frame: 24 months ]
Secondary Outcome Measures
:
- Description of Quality of life by Functional Assessment of Cancer Therapy - Lung including Life Stressor Checklist (FACT-L including LSC) [ Time Frame: baseline ]
- Description of Quality of life by Functional Assessment of Cancer Therapy - Lung including Life Stressor Checklist (FACT-L including LSC) [ Time Frame: From baseline to 3 months ]
- Description of Quality of life by Life Stressor Checklist - Lung (LSC-L) [ Time Frame: From 3 months to 6 months ]
- Description of Quality of life by Life Stressor Checklist - Lung (LSC-L) [ Time Frame: From 6 months to 12 months ]
- Description of Quality of life by Life Stressor Checklist - Lung (LSC-L) [ Time Frame: From 12 months to 18 months ]
- Description of Quality of life by Life Stressor Checklist - Lung (LSC-L) [ Time Frame: From 18 months to 24 months ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | up to 130 Years (Child, Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Study Population
Hospital, clinic
Criteria
Inclusion Criteria:
- Patients treated with Iressa
Exclusion Criteria:
- Patient included in a therapeutic trial comprising protocol use of Iressa
- Patient included in a therapeutic trial (Huriet-Serusclat Act)
- Patient refusing to participate in the study
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01448187
Locations
| France | |
| Research Site | |
| Aulnay Sous Bois, France | |
| Research Site | |
| Bayonne, France | |
| Research Site | |
| Bordeaux, France | |
| Research Site | |
| Bron, France | |
| Research Site | |
| Carcassonne, France | |
| Research Site | |
| Chalon Sur Saone, France | |
| Research Site | |
| Cholet, France | |
| Research Site | |
| Clamart, France | |
| Research Site | |
| Colmar, France | |
| Research Site | |
| Corbeil Essonnes, France | |
| Research Site | |
| Creteil, France | |
| Research Site | |
| Epernay, France | |
| Research Site | |
| La Source, France | |
| Research Site | |
| Macon, France | |
| Research Site | |
| Marseille, France | |
| Reseacrh Site | |
| Metz, France | |
| Research Site | |
| Mont de Marsan, France | |
| Research Site | |
| Niort, France | |
| Research Site | |
| Paris, France | |
| Research Site | |
| Pierre Benite, France | |
| Research Site | |
| Quimper, France | |
| Research Site | |
| Reims, France | |
| Research Site | |
| Rouen, France | |
| Research Site | |
| St Herblain, France | |
| Research Site | |
| St Nazaire, France | |
| Research Site | |
| St Omer, France | |
| Research Site | |
| Strasbourg, France | |
| Research Site | |
| Toulon, France | |
| Research Site | |
| Vienne, France | |
Sponsors and Collaborators
AstraZeneca
Investigators
| Principal Investigator: | Thierry BOUILLET, Dr | Bobigny | |
| Principal Investigator: | Elisabeth BRAMBILLA, Pr | Grenoble | |
| Principal Investigator: | Jacques CADRANEL, Pr | Paris | |
| Principal Investigator: | Jean-Francois MORERE, Pr | Bobigny | |
| Principal Investigator: | Maurice PEROL, Dr | Lyon | |
| Principal Investigator: | Virginie RONDEAU, PhD | Bordeaux |
Additional Information:
| Responsible Party: | AstraZeneca |
| ClinicalTrials.gov Identifier: | NCT01448187 History of Changes |
| Other Study ID Numbers: |
NIS-OFR-IRE-2011/1 |
| First Posted: | October 7, 2011 Key Record Dates |
| Last Update Posted: | July 4, 2016 |
| Last Verified: | July 2016 |
Keywords provided by AstraZeneca:
|
Lung cancer, France |